What next for CRISPR after first therapeutic approvals?
SelectScience,
As we celebrate the first regulatory approval of a gene-editing based therapeutic, Casgevy™, for the treatment of sickle cell…
As we celebrate the first regulatory approval of a gene-editing based therapeutic, Casgevy™, for the treatment of sickle cell…
The approval of the first Crispr-based therapy is just the beginning. Getting it to patients is the next hurdle.
In a 2008 issue of Science, just a page apart, were the two crucial discoveries that would form the cure for sickle cell disease.
CRISPR screening enables the rapid and unbiased identification of genes relevant to a specific biological pathway.
Premium Courtesy of CG Oncology; Chris Conroy Photography; Mahmee; Alyssa Powell/Insider This story is available exclusively to…
Scientists have now drafted a complete version of the human genome sequence — but the job of deciphering our DNA has only just…
CRISPR has been grabbing headlines because of its potential as a form of gene therapy.
October 12th, 2016 Xconomy San Francisco — Another academic group has published results of animal experiments that use the gene…
Researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center have found that changes to a small stretch of…
A direct consequence of natural selection among Homo sapiens, sickle cell disease (SCD) has afflicted a large segment of the…
Researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center have found that changes to a small stretch of…
Researchers from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center have found that changes to a small stretch of…
Researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center have found that changes to a small stretch of…
NEW YORK (GenomeWeb) – Scientists have developed a gene editing strategy that could help treat sickle cell disease by short-circu…
Home Medical…
BOSTON (September 16, 2015) - Researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center have found that…